CEL-SCI Corp (CVM)
1.45
-0.01
(-0.68%)
USD |
NYAM |
Apr 25, 16:00
1.48
+0.03
(+2.07%)
After-Hours: 20:00
CEL-SCI Research and Development Expense (Quarterly): 4.352M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.352M |
| September 30, 2023 | 5.268M |
| June 30, 2023 | 5.728M |
| March 31, 2023 | 6.084M |
| December 31, 2022 | 5.392M |
| September 30, 2022 | 6.462M |
| June 30, 2022 | 6.287M |
| March 31, 2022 | 6.524M |
| December 31, 2021 | 6.083M |
| September 30, 2021 | 5.290M |
| June 30, 2021 | 7.182M |
| March 31, 2021 | 5.222M |
| December 31, 2020 | 5.415M |
| September 30, 2020 | 5.160M |
| June 30, 2020 | 3.969M |
| March 31, 2020 | 4.458M |
| December 31, 2019 | 4.253M |
| September 30, 2019 | 3.390M |
| June 30, 2019 | 2.966M |
| March 31, 2019 | 2.832M |
| December 31, 2018 | 3.472M |
| September 30, 2018 | 3.201M |
| June 30, 2018 | 2.426M |
| March 31, 2018 | 2.962M |
| December 31, 2017 | 2.326M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.300M |
| June 30, 2017 | 3.180M |
| March 31, 2017 | 6.579M |
| December 31, 2016 | 3.548M |
| September 30, 2016 | 4.239M |
| June 30, 2016 | 4.362M |
| March 31, 2016 | 4.152M |
| December 31, 2015 | 4.693M |
| September 30, 2015 | 3.490M |
| June 30, 2015 | 5.728M |
| March 31, 2015 | 5.076M |
| December 31, 2014 | 4.855M |
| September 30, 2014 | 2.639M |
| June 30, 2014 | 4.454M |
| March 31, 2014 | 4.154M |
| December 31, 2013 | 4.020M |
| September 30, 2013 | 3.472M |
| June 30, 2013 | 3.770M |
| March 31, 2013 | 2.516M |
| December 31, 2012 | 2.925M |
| September 30, 2012 | 2.849M |
| June 30, 2012 | 2.469M |
| March 31, 2012 | 2.594M |
| December 31, 2011 | 2.456M |
| September 30, 2011 | 2.514M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.966M
Minimum
Jun 2019
7.182M
Maximum
Jun 2021
5.236M
Average
5.290M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp | 363.00M |
| The Cigna Group | -- |
| Synlogic Inc | 10.14M |
| BioXcel Therapeutics Inc | 9.934M |
| IGM Biosciences Inc | 54.19M |